Ebpay生命医药出版社

Ebpay生命

100763

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





已发表论文

阿布昔替尼与度普利尤单抗治疗特应性皮炎疗效的比较分析

 

Authors Song D, Gong WP, Xiao GL

Received 1 January 2025

Accepted for publication 13 March 2025

Published 6 April 2025 Volume 2025:18 Pages 817—825

DOI http://doi.org/10.2147/CCID.S515200

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg

Dan Song, Wei-Ping Gong, Gui-Lin Xiao

Department of Dermatology, Zhoushan Hospital, Zhoushan City, Zhejiang Province, 316000, People’s Republic of China

Correspondence: Dan Song, Department of Dermatology, Zhoushan Hospital, No. 739, Dingshen Road, Zhoushan City, Zhejiang Province, 316000, People’s Republic of China, Email SongDan127@163.com

Background: This study compares the efficacy and safety of Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, and Dupilumab, an interleukin-4 and interleukin-13 inhibitor, in the treatment of Atopic dermatitis (AD).
Methods: A retrospective study was conducted on 136 patients with moderate to severe AD, treated with either Abrocitinib (n=60) or Dupilumab (n=76) from June 2022 to June 2024. Abrocitinib was administered at 100 mg/day orally, and Dupilumab at 300 mg subcutaneously every two weeks after a 600 mg loading dose. Primary outcome measures included serum immunoglobulin E (IgE) levels, eosinophil (Egb) counts, and clinical symptom improvement, assessed by the Eczema Area and Severity Index (EASI), Numeric Rating Scale (NRS) for pruritus, and Scoring Atopic Dermatitis (SCORAD). Quality of life was evaluated using the Dermatology Life Quality Index (DLQI), while emotional distress was assessed through the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS). The incidence of adverse reactions was also recorded. Statistical significance was determined using t-tests and Chi-square tests (p < 0.05).
Results: Both treatments reduced IgE and eosinophil levels with no significant inter-group differences (p > 0.05). Abrocitinib was more effective in reducing pruritus, with a greater reduction in NRS scores (p < 0.05). EASI, SCORAD, DLQI, SAS and SDS improvements were similar, though Abrocitinib showed a greater reduction in anxiety (p = 0.011). The overall effective rate was higher in the Abrocitinib group (80.00%) compared to Dupilumab (69.73%) but not significantly (p = 0.174). Adverse reactions were minimal and comparable, with incidences of 8.33% for Abrocitinib and 9.21% for Dupilumab (p = 0.858).
Conclusion: Both Abrocitinib and Dupilumab are effective and well-tolerated treatments for atopic dermatitis. While their overall efficacy and safety profiles are comparable, Abrocitinib offers superior relief of pruritus. Both therapies represent valuable options in the management of moderate to severe atopic dermatitis.

Keywords: atopic dermatitis, Abrocitinib, Dupilumab, Janus kinase 1 inhibitor, interleukin-4 inhibitor

Download Article[PDF]